Recombinant Human Erythropoietin Shortens the Bleeding Time and Corrects the Abnormal Platelet Aggregation in Hemodialysis Patients

Abstract

Comment: Anesthesiologists should not use this study to lessen their concern about platelet dysfunction in patients with end-stage renal disease. The study encompassed only eight patients and excluded patients with diabetes, die most common cause of renal failure for many years. Three of die eight patients continued to have abnormal bleeding times after erythropoietin therapy. Platelet aggregation was improved with erythropoietin therapy, but the relationship of this test to in vivo platelet function is not clear